Xeris Biopharma Holdings, Inc. XERS
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is an endocrine/women's health drug developer. Its lead program, Recorlev, Gvoke, Keveyis (commercial portfolio), is in Phase 2 for Cushing's syndrome (endogenous hypercortisolemia); severe hypoglycemia; primary periodic paralysis. Its next catalyst on record is XP-8121: Initiate Phase 3 clinical trial (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: XP-8121 — Initiate Phase 3 clinical trial (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Recorlev (levoketoconazole) | endogenous hypercortisolemia in Cushing's syndrome | small molecule | Approved |
| Gvoke (ready-to-use liquid glucagon: PFS, HypoPen, Kit) | severe hypoglycemia (ages 2+) | protein/peptide | Approved |
| Keveyis (dichlorphenamide) | primary periodic paralysis | small molecule | Approved |
| XP-8121 (once-weekly SC levothyroxine, XeriSol) | hypothyroidism ('Phase 3-ready'; Phase 3 trial planned, FDA discussions ongoing) | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 endocrine/women's health companies
- AbCellera Biologics Inc. ABCL
- MBX Biosciences, Inc. MBX
- Entera Bio Ltd. ENTX
- Vogenx, Inc. VOGX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.